MarketLens Is the GLP-1 Market Still a Blockbuster Opportunity for Investors Key Takeaways The GLP-1 analogue market is exploding, projected to reach $268.4 billion by 2030 with a 30.6% CAGR , driven by rising obesity and diabetes rates and expanded therapeutic indications
diabetic gastroparesis, may be linked to upper gastrointestinal symptoms for which current treatment remains suboptimal
As these innovations progress through clinical development and regulatory approval, they are likely to increase patient adherence, broaden treatment eligibility, and create new commercial opportunities across obesity, diabetes, and other metabolic disorders
Common examples include semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound)
Our entire dedicated team is here to guide you through your weight loss journey to redefine whats possible in weight management
Abbasinejad evaluates every patient personally, but generally, the ideal candidate falls into one of the following categories: BMI Criteria: Adults with a Body Mass Index (BMI) of 30 or higher (obesity), or a BMI of 27 or higher (overweight) who also have at least one weight-related medical condition, such as hypertension, high cholesterol , or type 2 diabetes
